Cargando…
Persistence of Babesia microti Infection in Humans
Persistent infection is a characteristic feature of babesiosis, a worldwide, emerging tick-borne disease caused by members of the genus Babesia. Persistence of Babesia infection in reservoir hosts increases the probability of survival and transmission of these pathogens. Laboratory tools to detect B...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789900/ https://www.ncbi.nlm.nih.gov/pubmed/31319461 http://dx.doi.org/10.3390/pathogens8030102 |
_version_ | 1783458720216252416 |
---|---|
author | Bloch, Evan M. Kumar, Sanjai Krause, Peter J. |
author_facet | Bloch, Evan M. Kumar, Sanjai Krause, Peter J. |
author_sort | Bloch, Evan M. |
collection | PubMed |
description | Persistent infection is a characteristic feature of babesiosis, a worldwide, emerging tick-borne disease caused by members of the genus Babesia. Persistence of Babesia infection in reservoir hosts increases the probability of survival and transmission of these pathogens. Laboratory tools to detect Babesia in red blood cells include microscopic detection using peripheral blood smears, nucleic acid detection (polymerase chain reaction and transcription mediated amplification), antigen detection, and antibody detection. Babesia microti, the major cause of human babesiosis, can asymptomatically infect immunocompetent individuals for up to two years. Chronically infected blood donors may transmit the pathogen to another person through blood transfusion. Transfusion-transmitted babesiosis causes severe complications and death in about a fifth of cases. Immunocompromised patients, including those with asplenia, HIV/AIDS, malignancy, or on immunosuppressive drugs, often experience severe disease that may relapse up to two years later despite anti-Babesia therapy. Persistent Babesia infection is promoted by Babesia immune evasive strategies and impaired host immune mechanisms. The health burden of persistent and recrudescent babesiosis can be minimized by development of novel therapeutic measures, such as new anti-parasitic drugs or drug combinations, improved anti-parasitic drug duration strategies, or immunoglobulin preparations; and novel preventive approaches, including early detection methods, tick-avoidance, and blood donor screening. |
format | Online Article Text |
id | pubmed-6789900 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67899002019-10-16 Persistence of Babesia microti Infection in Humans Bloch, Evan M. Kumar, Sanjai Krause, Peter J. Pathogens Review Persistent infection is a characteristic feature of babesiosis, a worldwide, emerging tick-borne disease caused by members of the genus Babesia. Persistence of Babesia infection in reservoir hosts increases the probability of survival and transmission of these pathogens. Laboratory tools to detect Babesia in red blood cells include microscopic detection using peripheral blood smears, nucleic acid detection (polymerase chain reaction and transcription mediated amplification), antigen detection, and antibody detection. Babesia microti, the major cause of human babesiosis, can asymptomatically infect immunocompetent individuals for up to two years. Chronically infected blood donors may transmit the pathogen to another person through blood transfusion. Transfusion-transmitted babesiosis causes severe complications and death in about a fifth of cases. Immunocompromised patients, including those with asplenia, HIV/AIDS, malignancy, or on immunosuppressive drugs, often experience severe disease that may relapse up to two years later despite anti-Babesia therapy. Persistent Babesia infection is promoted by Babesia immune evasive strategies and impaired host immune mechanisms. The health burden of persistent and recrudescent babesiosis can be minimized by development of novel therapeutic measures, such as new anti-parasitic drugs or drug combinations, improved anti-parasitic drug duration strategies, or immunoglobulin preparations; and novel preventive approaches, including early detection methods, tick-avoidance, and blood donor screening. MDPI 2019-07-17 /pmc/articles/PMC6789900/ /pubmed/31319461 http://dx.doi.org/10.3390/pathogens8030102 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bloch, Evan M. Kumar, Sanjai Krause, Peter J. Persistence of Babesia microti Infection in Humans |
title | Persistence of Babesia microti Infection in Humans |
title_full | Persistence of Babesia microti Infection in Humans |
title_fullStr | Persistence of Babesia microti Infection in Humans |
title_full_unstemmed | Persistence of Babesia microti Infection in Humans |
title_short | Persistence of Babesia microti Infection in Humans |
title_sort | persistence of babesia microti infection in humans |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789900/ https://www.ncbi.nlm.nih.gov/pubmed/31319461 http://dx.doi.org/10.3390/pathogens8030102 |
work_keys_str_mv | AT blochevanm persistenceofbabesiamicrotiinfectioninhumans AT kumarsanjai persistenceofbabesiamicrotiinfectioninhumans AT krausepeterj persistenceofbabesiamicrotiinfectioninhumans |